Mycophenolate in Psoralen-UV-A Desensitization Therapy for Chronic Actinic Dermatitis

Chronic actinic dermatitis (CAD), a photosensitive dermatosis, is characterized by inflammatory lesions, especially on sun-exposed skin. However, its pathogenesis remains unclear. In this study, second-generation RNA sequencing and comprehensive bioinformatics analyses of mRNAs and long noncoding RNAs (lncRNAs) were performed to determine the transcriptome profiles of patients with CAD. A total 6889 annotated lncRNAs, 341 novel lncRNAs, and 65091 mRNAs were identified. Interestingly, patients with CAD and healthy controls showed distinct transcriptome profiles. Indeed, 198 annotated (81.48%) and 45 novel (18.52%) lncRNAs were differentially expressed between the two groups. GO, KEGG, and RGSEA analyses of lncRNAs showed that inflammatory and immune response related pathways played crucial roles in the pathogenetic mechanism of CAD. In addition, we unveiled key differentially expressed lncRNAs, including lncRNA RP11-356I2.4 which plays a role probably by regulating TNFAIP3 and inflammation. qRT-PCR data validated the differentially expressed genes. The newly identified lncRNAs may have potential roles in the development of CAD; these findings lay a solid foundation for subsequent functional exploration of lncRNAs and mRNAs as therapeutic targets for CAD.

Download Full-text

Abstract 16877: Correlation of Antibody Binding Strength to Complement Fixation

Circulation ◽

10.1161/circ.130.suppl_2.16877 ◽

2014 ◽

Vol 130 (suppl_2) ◽

Author(s):

Vishal Y Parikh ◽

Nancy Reinsmoen ◽

Jignesh Patel ◽

Zhe Yu ◽

Frank Liou ◽

...

Keyword(s):

Fluorescence Intensity ◽

Heart Transplant ◽

Binding Assay ◽

Complement Fixation ◽

Antibody Binding ◽

Binding Ability ◽

Binding Strength ◽

Desensitization Therapy ◽

Positive Rate ◽

Correlation Statistics

Background: In patients (pts) who are highly sensitized, desensitization therapy is commonly applied to reduce antibody (Abs) load and to reduce potential morbidity and mortality following heart transplant (HTx). It is not known as to what level of antibody binding is needed to initiate desensitization therapy. It is believed that high binding Abs may have the ability to fix complement and lead to cytotoxicity. Methods: Between 2011 and 2012 we assessed 13 highly sensitized pts who were noted to have standardized fluorescence intensity (SFI) >100,000 pretransplant. A complement binding assay (C1q binding assay) was then applied to these Abs to assess for a correlation of binding to cytotoxicity. Correlation statistics were used to derive significance between higher antibody binding and capacity to bind complement. Results: There seems to be no correlation between the different binding strength and C1q positivity. However, when evaluating Luminex 1:8 test, there seems to be correlation between class I binding strength with C1q positivity. There was C1q positive rate of 10.8% in SFI 200,000 range. Conclusions: Undiluted antibodies do not correlate to C1q binding ability. However the 1:8 dilution test seems to provide an better prediction of complement binding. 1:8 dilutions should be performed to accurately assess the ability for antibodies to bind complement.

Download Full-text

Chronic actinic dermatitis

Dermatology Online Journal ◽

10.5070/d386r0b00h ◽

2003 ◽

Vol 9 (4) ◽

Author(s):

Lesley Clark-Loeser

Keyword(s):

Chronic Actinic Dermatitis

Download Full-text